MENU
+Compare
RCUS
Stock ticker: NYSE
AS OF
Nov 21, 04:59 PM (EDT)
Price
$22.04
Change
+$0.80 (+3.77%)
Capitalization
2.73B

RCUS Arcus Biosciences Forecast, Technical & Fundamental Analysis

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company... Show more

RCUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for RCUS with price predictions
Nov 21, 2025

Aroon Indicator for RCUS shows an upward move is likely

RCUS's Aroon Indicator triggered a bullish signal on November 07, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 192 similar instances where the Aroon Indicator showed a similar pattern. In of the 192 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 18, 2025. You may want to consider a long position or call options on RCUS as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on November 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RCUS broke above its upper Bollinger Band on November 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.258) is normal, around the industry mean (27.205). P/E Ratio (0.000) is within average values for comparable stocks, (51.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.881). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (9.251) is also within normal values, averaging (328.409).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
RCUS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

RCUS is expected to report earnings to fall 7.87% to -116 cents per share on February 25

Arcus Biosciences RCUS Stock Earnings Reports
Q4'25
Est.
$-1.17
Q3'25
Beat
by $0.01
Q2'25
Beat
by $1.12
Q1'25
Missed
by $0.12
Q4'24
Beat
by $0.20
The last earnings report on October 28 showed earnings per share of -126 cents, beating the estimate of -127 cents. With 2.02M shares outstanding, the current market capitalization sits at 2.73B.
A.I. Advisor
published General Information

General Information

a company which offers pre-clinical drug discovery and development solutions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
3928 Point Eden Way
Phone
+1 510 694-6200
Employees
577
Web
https://www.arcusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGSMX22.990.59
+2.63%
JPMorgan Small Cap Growth R6
APDLX15.370.28
+1.86%
Artisan Value Advisor
MGRQX42.910.49
+1.16%
MFS International Growth R2
GGEFX25.87N/A
N/A
Summitry Equity Fund
FHJMX43.98N/A
N/A
Fidelity Advisor Europe I

RCUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
+3.86%
XNCR - RCUS
54%
Loosely correlated
+1.77%
IDYA - RCUS
51%
Loosely correlated
+2.50%
IMNM - RCUS
50%
Loosely correlated
+5.94%
APGE - RCUS
49%
Loosely correlated
+4.56%
RLAY - RCUS
48%
Loosely correlated
+6.11%
More